Back to Archived Journals » Antibody Technology Journal » Volume 6

Broadly neutralizing antibodies for therapy of viral infections

Authors Srinivasan S, Ghosh M, Maity S, Varadarajan R

Received 10 July 2015

Accepted for publication 29 October 2015

Published 8 January 2016 Volume 2016:6 Pages 1—15

DOI https://doi.org/10.2147/ANTI.S92190

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Professor Ashraf Tabll

Peer reviewer comments 2

Editor who approved publication: Professor Shixia Wang


Sankaranarayanan Srinivasan,1 Maloy Ghosh,1 Sunit Maity,1 Raghavan Varadarajan2

1Theramyt Novobiologics Private Limited, 2Molecular Biophysics Unit, Indian Institute of Science, Bangalore, India

Abstract: Neutralizing antibodies (NAbs) are an essential part of the human immune response that involves an intricate relationship between the innate and adaptive immune system to prevent infection. The appearance of NAbs is a hallmark of viral infection in patients with HIV, dengue, hepatitis C virus, Ebola, and influenza. These viruses are characterized by high genetic diversity of viral epitopes arising due to a high replication rate and an error-prone replication machinery. In general, almost all infected individuals develop strain-specific NAbs in a fairly short period of time. In contrast, broadly neutralizing antibodies (bNAbs) show subdominant responses and are found only in a subset of patients, typically after a lengthy period of infection. Epitopes targeted by specific NAbs and bNAbs evolved thereafter provide useful information for vaccine design. In this review, we discuss the isolation and utility of bNAbs against HIV-1, dengue, hepatitis C virus, influenza, and Ebola. Passive antibody therapy and the economics of NAb therapy are also discussed.

Keywords: neutralizing antibodies, HIV, dengue, hepatitis C, influenza

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]